Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02734823

Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor

Long Term Effects of Tyrosine Kinase Inhibitors on Ovarian Reserve and Fertility, A Pilot Study

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
University of Southern California · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

This pilot research trial studies the long term effects of tyrosine kinase inhibitor therapy on ovarian reserve and fertility in patients with chronic myeloid leukemia or gastrointestinal stromal tumor. Studying ovary imaging, ovarian reserve markers, and hormone levels from patients receiving tyrosine kinase inhibitor therapy may help doctors learn more about the effects of tyrosine kinase inhibitor therapy on ovarian function and fertility.

Detailed description

PRIMARY OBJECTIVES: I. To collect preliminary information to help design a study to look at longitudinal changes in markers of ovarian reserve and menstruation in premenopausal women undergoing tyrosine kinase inhibitors (TKI) therapy. SECONDARY OBJECTIVES: I. Evaluate ovarian response to controlled ovarian hyperstimulation in patients who elect to undergo in vitro fertilization (IVF) for fertility preservation. OUTLINE: Patients undergo transvaginal ultrasound for antral follicles analysis and collection of serum for ovarian reserve markers and hormonal analysis before TKI therapy and at 12, 24, and 48 weeks.

Conditions

Interventions

TypeNameDescription
OTHERCytology Specimen Collection ProcedureUndergo collection of serum
OTHERLaboratory Biomarker AnalysisCorrelative studies
OTHERQuestionnaire AdministrationAncillary studies
PROCEDUREUltrasonographyUndergo transvaginal pelvic ultrasonography

Timeline

Start date
2016-03-01
Primary completion
2024-03-14
Completion
2024-03-14
First posted
2016-04-12
Last updated
2024-03-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02734823. Inclusion in this directory is not an endorsement.